^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRS-4642

    i
    Associations
    News

    Trials

    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (NCT06770452)
    Phase 2
    Zhejiang University
    Not yet recruiting
    Last update posted :
    01/13/2025
    Initiation :
    02/01/2025
    Primary completion :
    02/01/2027
    Completion :
    02/01/2028
    KRAS
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (NCT06587061)
    Phase 2
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    09/19/2024
    Initiation :
    10/01/2024
    Primary completion :
    06/01/2027
    Completion :
    12/01/2027
    CA 19-9
    |
    gemcitabine • albumin-bound paclitaxel • HRS-4642
    A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT06385678)
    Phase 1/2
    Jiangsu HengRui Medicine Co., Ltd.
    Not yet recruiting
    Last update posted :
    04/26/2024
    Initiation :
    05/01/2024
    Primary completion :
    10/01/2025
    Completion :
    08/01/2026
    KRAS
    |
    cisplatin • carboplatin • pemetrexed • Ariely (adebrelimab) • HRS-4642 • tizetatug rezetecan (SHR-A1921)
    Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT05533463)
    Phase 1
    Jiangsu HengRui Medicine Co., Ltd.
    Recruiting
    Last update posted :
    11/06/2023
    Initiation :
    09/15/2022
    Primary completion :
    04/30/2024
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    HRS-4642